CRIS Current Research Information System

RIZZO, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.132
NA - Nord America 2.516
EU - Europa 1.733
SA - Sud America 185
AF - Africa 180
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 7.748
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.482
SG - Singapore 1.120
CN - Cina 982
IT - Italia 419
HK - Hong Kong 295
SE - Svezia 287
VN - Vietnam 269
DE - Germania 209
GB - Regno Unito 177
KR - Corea 177
BR - Brasile 133
IN - India 129
CH - Svizzera 127
IE - Irlanda 110
NL - Olanda 91
RU - Federazione Russa 83
FI - Finlandia 79
CI - Costa d'Avorio 67
SC - Seychelles 44
ID - Indonesia 41
FR - Francia 31
JO - Giordania 30
TG - Togo 26
BG - Bulgaria 23
JP - Giappone 23
AT - Austria 22
AR - Argentina 21
CA - Canada 19
TR - Turchia 19
NG - Nigeria 18
PL - Polonia 16
MX - Messico 13
ZA - Sudafrica 12
GR - Grecia 11
UA - Ucraina 11
BE - Belgio 8
BD - Bangladesh 7
EC - Ecuador 7
IQ - Iraq 7
LT - Lituania 7
CL - Cile 6
CO - Colombia 6
ES - Italia 5
IR - Iran 5
PS - Palestinian Territory 5
PY - Paraguay 4
VE - Venezuela 4
AE - Emirati Arabi Uniti 3
HU - Ungheria 3
KZ - Kazakistan 3
MA - Marocco 3
TH - Thailandia 3
CD - Congo 2
DK - Danimarca 2
GH - Ghana 2
KE - Kenya 2
MY - Malesia 2
PE - Perù 2
PH - Filippine 2
PK - Pakistan 2
PT - Portogallo 2
RO - Romania 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
TN - Tunisia 2
UY - Uruguay 2
UZ - Uzbekistan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AU - Australia 1
AZ - Azerbaigian 1
BY - Bielorussia 1
CG - Congo 1
CY - Cipro 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EE - Estonia 1
HT - Haiti 1
IL - Israele 1
LB - Libano 1
LV - Lettonia 1
SA - Arabia Saudita 1
TW - Taiwan 1
Totale 7.748
Salva come PNG Salva come JPEG
Città #
Singapore 738
Hefei 372
Ashburn 295
Hong Kong 292
Dallas 242
Chandler 226
Seoul 171
Beijing 140
Santa Clara 129
Bern 124
Southend 122
Boardman 120
Fairfield 116
Dublin 110
Princeton 107
Bologna 104
Dong Ket 96
Los Angeles 70
Abidjan 67
Ho Chi Minh City 57
Helsinki 52
New York 49
Redondo Beach 45
Hanoi 44
Houston 43
Redmond 41
Woodbridge 41
Buffalo 38
Seattle 38
Bengaluru 34
Milan 34
Jakarta 33
Wilmington 33
Amman 30
Boydton 30
Cambridge 29
Guangzhou 27
Lomé 26
Florence 24
Berlin 22
Frankfurt am Main 22
London 21
Chicago 20
Lappeenranta 20
São Paulo 20
Tokyo 20
Turin 20
Munich 19
Sofia 19
San Diego 17
Shanghai 16
Rome 15
Tongling 14
Abeokuta 13
Medford 13
Vienna 12
Castel Maggiore 11
Nuremberg 11
Zhengzhou 10
Brooklyn 9
Des Moines 9
Istanbul 9
Amsterdam 8
Ann Arbor 8
Biên Hòa 8
Brussels 8
Hyderabad 8
Nanjing 8
Olalla 8
Phoenix 8
Warsaw 8
Changsha 7
Haiphong 7
Harbin 7
Turku 7
Yubileyny 7
Council Bluffs 6
Hải Dương 6
Mexico City 6
Montreal 6
Poplar 6
Rio de Janeiro 6
Shenzhen 6
Chennai 5
Chongqing 5
Da Nang 5
Denver 5
Elk Grove Village 5
Falkenstein 5
Genoa 5
Groningen 5
Halhul 5
Izmir 5
Jinan 5
Orem 5
Paris 5
Quận Bình Thạnh 5
San Francisco 5
San Jose 5
Shenyang 5
Totale 4.985
Salva come PNG Salva come JPEG
Nome #
Adjuvant treatment in biliary tract cancer 317
Specific Toxicity of Maintenance Olaparib Versus Placebo in Advanced Malignancies: A Systematic Review and Meta-analysis 272
Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: A proof of concept 184
How to choose between percutaneous transhepatic and endoscopic biliary drainage in malignant obstructive jaundice: An updated systematic review and meta-analysis 182
Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report 176
Second-line treatment in advanced biliary tract cancer: Today and tomorrow 176
Anti-EGFR monoclonal antibodies in advanced biliary tract cancer: A systematic review and meta-analysis 169
Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies 165
Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma 161
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumour Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 157
Challenges in Repurposing Drugs in COVID-19 Pandemic. Debating on Potential New Refinements 151
Intensive follow-up program and oncological outcomes of 278 biliary tract cancer patients after curative intent surgery: A single-center retrospective experience 147
Bone targeting agents in patients with metastatic prostate cancer: State of the art 139
Genomic Database Analysis of Uterine Leiomyosarcoma Mutational Profile 135
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 131
Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw 130
Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand? 129
Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study 128
Wilson disease, ABCC2 c.3972C > T polymorphism and primary liver cancers: suggestions from a familial cluster 124
Is post-transplant chemotherapy feasible in liver transplantation for colorectal cancer liver metastases? 119
Hacking pancreatic cancer: Present and future of personalized medicine 119
Skull Metastasis From Uterine Leiomyosarcoma, a Rare Presentation for a Rare Tumor: A Case Report and Review of the Literature 116
Impact of Chemotherapy in the Adjuvant Setting of Early Stage Uterine Leiomyosarcoma: A Systematic Review and Updated Meta-Analysis 115
Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis 113
Adjuvant therapy in renal cell carcinoma: Is it the right strategy to inhibit VEGF? 111
Experimental HER2- targeted therapies for biliary tract cancer 111
Genomics and Immunomics in the Treatment of Urothelial Carcinoma 109
The Identity of PDGFRA D842V-Mutant Gastrointestinal Stromal Tumors (GIST) 107
The power of kindness: curative treatment with metronomic combination in advanced hepatocellular carcinoma 97
Molecular features and targeted therapies in extrahepatic cholangiocarcinoma: Promises and failures 97
Metabolomic profiling in renal cell carcinoma patients: News and views 94
Third-and later-line treatment in advanced or metastatic gastric cancer: A systematic review and meta-analysis 94
Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors 93
Encephalic Leukocytoclastic Vasculitis during Treatment with Sunitinib for Renal Cell Carcinoma: A Case Report 86
Dynamics of resistance to immunotherapy and TKI in patients with advanced renal cell carcinoma 86
Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges 83
Adjuvant systemic treatment in resected biliary tract cancer: State of the art, controversies, and future directions 80
Novel HER2-directed treatments in advanced gastric carcinoma: Another paradigm shift? 80
Cancer Immunotherapy: Harnessing the Immune System to Fight Cancer 79
The Impact of Concomitant Proton Pump Inhibitors on Immunotherapy Efficacy Among Patients with Urothelial Carcinoma: A Meta-Analysis 78
Hypothesis on the possible relevance of the immunogenic cell death in the treatment of gestational trophoblastic neoplasms 78
Combination therapy of dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer 77
Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials 73
Cancer immunotherapy: Current and future perspectives on a therapeutic revolution 72
Recurrent Uterine Smooth-Muscle Tumors of Uncertain Malignant Potential (STUMP): State of The Art 69
Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review 69
Pathologic Complete Response in Urothelial Carcinoma Patients Receiving Neoadjuvant Immune Checkpoint Inhibitors: A Meta-Analysis 68
FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue 68
Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials 65
Detecting and targeting NTRK gene fusions in cholangiocarcinoma: news and perspectives 65
Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer 65
First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: “And Yet It Moves!” 63
Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma 63
A meta-analysis on overall survival and safety outcomes in patients with nonmetastatic castration-resistant prostate cancer treated with novel hormonal agents 61
BILCAP trial and adjuvant capecitabine in resectable biliary tract cancer: reflections on a standard of care 60
Microbiota and prostate cancer 59
Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives 58
Second-line FOLFOX chemotherapy for advanced biliary tract cancer 58
TRK inhibition in cholangiocarcinoma: Trying to teach an old dog new tricks 56
Renal Toxicities in Cancer Patients Receiving Immune-Checkpoint Inhibitors: A Meta-Analysis 56
IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver? 55
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis 48
Precision oncology in cholangiocarcinoma: current issues in clinical trial design and access to targeted therapies 48
Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis 45
The DNA damage repair (DDR) pathway in biliary tract cancer (BTC): A new Pandora's box? 45
Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma? 42
Ivosidenib in IDH-mutant cholangiocarcinoma: where do we stand? 42
Recent advances of immunotherapy for biliary tract cancer 41
Adjuvant Nivolumab in Muscle-Invasive Urothelial Carcinoma 40
Impact of clinicopathological features on immune-based combinations for advanced urothelial carcinoma: A meta-analysis 40
In Regard to “A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08)” 40
Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma 39
Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma 39
A brand-new CAR for macrophages: Is it time to fire up the engines of a new era for the treatment of renal cell carcinoma? 38
Cabozantinib for Treatment of Brain Metastases in Patients with Renal Cell Carcinoma 38
Atezolizumab in advanced hepatocellular carcinoma: Good things come to those who wait 38
Novel targeted therapies for advanced cholangiocarcinoma 38
The dilemma of neoadjuvant and adjuvant therapy in urothelial carcinoma: Will immunotherapy solve the problem? 37
DNA damage response alterations in gastric cancer: Knocking down a new wall 36
Systemic adjuvant treatment in hepatocellular carcinoma: Tempted to do something rather than nothing 36
Incidence of grade 3–4 adverse events, dose reduction, and treatment discontinuation in castration-resistant prostate cancer patients receiving PARP inhibitors: a meta-analysis 35
Assessing PD-L1 status in mRCC treated with first-line immune-based combinations: A meta-analysis 35
Apalutamide or enzalutamide in castration-sensitive prostate cancer: a number needed to treat analysis 34
Clinicopathological Features of FGFR3 - Mutated Upper Tract Urothelial Carcinoma: A Genomic Database Analysis 34
Pitfalls, challenges, and updates in adjuvant systemic treatment for resected biliary tract cancer 34
Adjuvant immunotherapy in muscle-invasive urothelial carcinoma 34
Toward personalized therapy for cholangiocarcinoma: new insights and challenges 33
An up-to-date evaluation of cabozantinib for the treatment of renal cell carcinoma 32
Risk of toxicity with immunotherapy-tyrosine kinase inhibitors for metastatic renal cell carcinoma: a meta-analysis of randomized controlled trials 32
Regarding “HER2 Overexpression as a Poor Prognostic Determinant in Resected Biliary Tract Cancer” 32
Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study 29
Determinants of treatment for first-line immune-based combinations in metastatic renal cell carcinoma: A critical overview of recent evidence 28
Adjuvant immunotherapy in muscle-invasive urothelial carcinoma 26
Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis 24
The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study 24
Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study 22
Randomized Clinical Trials in the Era of Precision Oncology - The Role of End Points, Industry Funding, and Medical Writing Integrity 19
Re: Hanbing Song, Bobak Seddighzadeh, Matthew R. Cooperberg, Franklin W. Huang. Expression of ACE2 and TMPRSS2, the SARS-CoV-2 Receptor and Co-Receptor, in Prostate Epithelial Cells. Eur Urol. In press DOI: 10.1016/j.eururo.2020.04.065 17
Considerations Regarding a Network Meta-analysis of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer 17
Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison 15
Totale 7.924
Salva come PNG Salva come JPEG
Categoria #
all - tutte 31.245
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.245
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021304 0 0 0 0 0 23 13 24 53 51 19 121
2021/2022756 41 11 23 42 39 17 16 50 173 54 183 107
2022/20231.462 97 132 60 106 148 163 63 92 223 66 107 205
2023/2024417 67 71 32 29 25 65 14 22 15 36 20 21
2024/20252.011 85 251 232 141 231 87 147 88 32 112 191 414
2025/20262.855 476 546 715 423 476 219 0 0 0 0 0 0
Totale 8.000